Background: The increasing survival of very low birthweight babies and the improvement of their management are not associated with a decreased incidence of cerebral palsy (CP). Among many risk factors, postnatal systemic steroids have been pointed out by clinical and experimental studies. The aim of this work is to explore the relationship between these treatments and CP at the age of two years in a population based cohort.
SUPERIORITY OF A NOVEL SURFACTANT, SURFAXIN (LUCINACTANT), OVER EXO-SURF (COLFOSCERIL PALMITATE) IN PREVNTING RESPIRATORY DISTRESS SYN-DROME IN VERY PRETERM INFANTS: A PIVOTAL , MULTINATIONAL, RANDOM-IZED TRIAL
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Background: Animal-derived, protein-containing surfactants perform better vs. non-protein-containing surfactants for the prevention and treatment of Respiratory Distress Syndrome (RDS). A new generation, non-animal-derived surfactant, Surfaxin, containing a peptide that mimics human SP-B, appears effective in animals and in early studies of infants with RDS.1 Our objective was to compare the efficacy and safety of Surfaxin vs. Exosurf in the prevention of RDS.
Methods: This was a Phase 3, pivotal, masked, multinational, randomized trial comparing Surfaxin (5.8 mL/kg or 175 mg/kg) vs. Exosurf for preventing RDS. Survanta® served as a reference arm in a 2:2:1 randomization strategy. Exosurf and Survanta were dosed per package insert. Inclusion criteria were: birth weight (BW) 600-1250 g, gestational age (GA) Ͻ32 wk, and successful intubation. Dosing occurred within 30 min of birth. Primary outcomes (adjudicated by an independent masked committee) were the incidence of RDS at 24 hours and RDS-related mortality by Day 14. Secondary outcomes included the occurrence of air leaks, incidence of bronchopulmonary dysplasia at the postconceptional ages of 28 days and 36 weeks, and other complications of prematurity. The trial was event-driven; primary outcomes and overall safety were assessed by an independent Data Safety Monitoring Board.
Results: Over 22 months, 49 centers randomized 1294 infants in BW strata of 600 -800 g, 801-1000 g, and 1001-1250 g. Overall BW and GA were 1001 g and 29.3 weeks, respectively. Primary outcome results are shown below: See 
Conclusion:
Surfaxin is significantly more efficacious than Exosurf in the prevention of RDS and in reducing RDS-related mortality through 14 days after birth. Background: Animal-derived, protein-containing surfactants perform better vs. non-protein-containing surfactants for prevention and treatment of Respiratory Distress Syndrome (RDS). A new generation, non-animal-derived surfactant, Surfaxin, containing a peptide that mimics the action of human SP-B, has been shown to be effective in animals, in studies of infants with RDS,1 and in large, controlled studies in the prevention of RDS in preterm infants. Our objective was to compare the incidence of all-cause mortality at Days 14 and 28, and at 36 weeks postconceptional age of Surfaxin vs. Survanta and Surfaxin vs. Curosurf across two clinical trials measuring their respective safety and efficacy in the prevention of RDS.
COMPARISON OF INCIDENCES OF ALL-CAUSE MORTALITY BETWEEN THE NOVEL SURFACTANT, SURFAXIN (LUCINACTANT) AND THE ANIMAL DERIVED SURFAC-TANTS SURVANTA (BERACTANT) AND CUROSURF (PORACTANT ALFA)
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Methods: A pooled analysis was performed across the only two Phase 3, masked, multinational, randomized trials comparing Surfaxin (5.8 mL/kg or 175 mg/kg) vs. Survanta (4.0 mL/kg or 100 mg/kg) and Curosurf (2.2 mL/kg or 175 mg/kg). All randomized patients were included. Endpoint definitions were the same for both trials. Adjustments were performed for birth weight (BW) strata and study centers. Inclusion criteria: BW 600-1250 g, gestational age Ͻ32 weeks, and successful intubation. Dosing and administration occurred within 30 min of birth. P values were calculated to assess treatment group differences using logistic regression adjusting for study center and BW strata.
Results: The pooled analysis of the two trials comparing Surfaxin with animal-derived surfactants is presented below: See 
Conclusion:
Combined data from these trials show lower all-cause mortality with Surfaxin than with the animal-derived surfactants (combined results of Survanta and Curosurf). Since Surfaxin has a higher concentration of surfactant apoprotein-equivalents-in the form of sinapultide-than any other commercially available surfactant, these results are consistent with the hypothesis that both the presence of, and a higher concentration of, surfactant protein amplify the benefits of surfactant therapy. Background: Respiration recovers faster in neonates resuscitated with ambient compared to 100% O 2. Matrix Metalloproteinase(MMPs) -9 and 2 play a role in pulmonary extracellular matrix remodelling and degradation after ischemia-reperfusion. The objective: Resuscitation of piglets with 100% oxygen is detrimental to pulmonary tissue compared to ambient air. We assessed MMP-9 and 2 in piglets after global hypoxia and subsequent resuscitation with ambient air or 100% O 2. Material and Methods: Sixty-nine piglets (12-36h of age) were resuscitated for 30min by ventilation with 21% or 100% O 2 after a hypoxic insult, and thereafter observed for 150min. In pulmonary tissue extracts and tracheal aspirate, MMPs were analysed by gelatine zymography and in situ zymography.
RESUSCITATION WITH 100% O 2 INCREASES PULMONARY MMPS IN HYPOXIC PIG-LETS
Results: In pulmonary tissue gelatin zymography pro-MMP-9 was increased in the resuscitated groups compared to baseline (pϽ0.005), pro-and active MMP-2 were increased in the group resuscitated with 100% oxygen compared to ambient air (pϽ0.005). In tracheal aspirate pro-MMP-9 and 2 were doubled in the ones resuscitated with 100% oxygen compared to ambient air. In situ zymography gave the same results.
Conclusion: 100% versus 21% oxygen for resuscitation of newborn piglets gives increased MMP-9 and 2 in pulmonary tissue and tracheal aspirate. Our data suggests that ambient air is less toxic to the lungs than 100% oxygen. Background: Reduced microbial exposure in early life may be partly responsible for an increase in atopic diseases in 'westernised' societies but the underlying mechanisms remain elusive. Objective To examine how exposure to bacterial lipopolysaccharide (LPS) during the first antigen encounter might influence the maturation of neonatal lymphoid cells, and to analyse possible differences in this respect between neonates with a high risk of allergy due to family history (FHϩ) and controls with no apparent risk (FH-).
IMPAIRED IL-4-ASSOCIATED GENERATION OF CCR4-EXPRESSING T CELLS IN NE-ONATES AT HEREDITARY ALLERGY RISK
Methods: Cord blood mononuclear cells from the FHϩ or FH-group were stimulated with pure LPS or â-lactoglobulin (â-LG) in its inherent LPS milieu. T-cell expression of chemokine receptors CCR4 and CXCR3 was determined by flow cytometry and RT-PCR. Cellular expression of IL-4 was analysed by quantitative RT-PCR, whereas IFN-ã was analysed by both quantitative RT-PCR and ELISA.
Results: Stimulation with LPS, or â-LG together with LPS, induced up-regulation of CCR4 (PϽ0.05) and CXCR3 (PϽ0.05). For CCR4 such up-regulation was related to the level of IL-4 produced by the same T cells (rSϭ0.49, Pϭ0.03), whereas CXCR3 expression was negatively correlated with the IL-4 levels (rSϭ-0.56, Pϭ0.02). Compared with the FHgroup, the FHϩ group showed a significantly lower capacity for induction of CCR4ϩ T cells (mean % of total T cells: FHϩ, 2.42% vs. FH-, 5.74%; PϽ0.01), and tended to express less IL-4 mRNA. Conversely, induction of CXCR3 and IFN-ã was not significantly different between the two groups. C Conclusion: When the immune system in early life encounters antigen together with LPS, T-cell localization for further immune induction within lymphoid tissue is facilitated by CCR4 and CXCR3 expression. In neonates at hereditary risk of allergy this homeostatic mechanism is jeopardised due to poorly up-regulated CCR4. Conversely, Th1 responses to antigen in the presence of LPS is not reduced compared with controls. Background: The hygiene hypothesis suggests that the increasing prevalence of allergy in "westernised" countries is due to reduced bacterial exposure in early life, but the underlying mechanism remains elusive. Objective: To analyse the effect of the bacterial product lipopolysaccharide (LPS) on the generation of regulatory T (T R) cells in neonates with allergy risk due to a family history of atopy (FH ϩ ) and in controls without such hereditary risk (FH -).
IMPAIRMENT OF PUTATIVE REGULATORY T CELLS IN CORD BLOOD FROM NEO-NATES WITH HEREDITARY ALLERGY RISK
Methods: Cord blood mononuclear cells from the FH ϩ and FH -groups were stimulated with bovine â-lactoglobulin in an inherent LPS milieu. T-cell phenotypes indicative of T R cells (CD25 ϩ , CD25 high and integrin áE ϩ ) and the proliferation antigen Ki-67 were quantified by flow cytometry. Release of TGF-â1 from its inactive complex was determined by ELISA.
Results: The FH ϩ group showed reduced capacity for generation of CD25 ϩ T cells (FH ϩ , 16.2% vs. FH -, 34.9%; pϽ0.01) and á E ϩ T cells (FH ϩ , 2.1% vs. FH -, 3.9%; pϽ0.05). Moreover, the CD25 high T cell subset tended to be impaired in the FH ϩ group (FH ϩ , 5.1% vs. FH -, 12.6%). The frequency of proliferating T cells was inversely related to the CD25 high phenotype (rϭ-0.54, pϽ0.05), and also to the activation-induced release of TGF-â1 (rϭ-0.80, pϽ0.001).
Conclusions: This study suggested that early-life exposure to a dietary antigen in physiological LPS milieu may generate T R cells, including the CD25 high phenotype that was shown to be related to TGF-â activity and suppressed proliferation. This capacity was impaired in neonates with hereditary allergy risk, but clinical follow-up will be required to determine the effect on allergy emergence.
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